Drug · DIN 02238682
PLAVIX
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since April 10, 2007; first marketed October 13, 1998.
- Drug Identification Number (DIN)
- 02238682
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Clopidogrel B01AC04
- Class
- Human
- Record last updated
- June 15, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CLOPIDOGREL (CLOPIDOGREL BISULFATE) | 75 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 29, 2006: NOC 7858New Drug Submission (NDS) · Manufacturer name change
- November 28, 2000: NOC 1027New Drug Submission (NDS)
- October 7, 1998: NOC 2748New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “plavix”. A notice may cover another product or only some lots: read it to see what it covers.
- Pradax (dabigatran etexilate) and Plavix (clopidogrel bisulfate) – Risk of Potential Patient Harm Associated with Brand Name Confusion – For the PublicNovember 8, 2011 · Drugs
- Pradax (dabigatran etexilate) and Plavix (clopidogrel bisulfate) - Risk of Potential Patient Harm Associated with Brand Name Confusion - For Health ProfessionalsNovember 8, 2011 · Drugs
- Plavix (blood thinner): New recommendations for use with proton pump inhibitors (antacids)September 22, 2011 · Drugs
Other DINs named PLAVIX
- DIN 02330555 · Cancelled Post Market